At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MLTX MoonLake Immunotherapeutics
Post-Mkt 06-08 18:17:34 EDT
18.00
+0.10
+0.56%
盘后18.24
+0.24+1.31%
18:15 EDT
High18.27Low17.84Vol1.21M
Open18.24D1 Closing17.90Amplitude2.40%
Mkt Cap1.33BTradable Cap707.66MTotal Shares73.62M
T/O21.83MT/O Rate3.08%Tradable Shares39.31M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Analysts Offer Insights on Healthcare Companies: Artiva Biotherapeutics, Inc. (ARTV), MoonLake Immunotherapeutics (MLTX) and MBX Biosciences, Inc. (MBX)
TIPRANKS  ·  00:40
Analysts Offer Insights on Healthcare Companies: Artiva Biotherapeutics, Inc. (ARTV), MoonLake Immunotherapeutics (MLTX) and MBX Biosciences, Inc. (MBX)
Moonlake’s Phase 3 Hidradenitis Trial Hits Completion, Setting Up Key Catalyst for MLTX
TIPRANKS  ·  00:30
Moonlake’s Phase 3 Hidradenitis Trial Hits Completion, Setting Up Key Catalyst for MLTX
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Hinge Health, Inc. Class A (HNGE) and MoonLake Immunotherapeutics (MLTX)
TIPRANKS  ·  06-08 19:50
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Hinge Health, Inc. Class A (HNGE) and MoonLake Immunotherapeutics (MLTX)
MoonLake Immunotherap Price Target Maintained With a $45.00/Share by HC Wainwright & Co.
Dow Jones  ·  06-08 18:53
MoonLake Immunotherap Price Target Maintained With a $45.00/Share by HC Wainwright & Co.
MoonLake Immunotherapeutics (MLTX) Valuation After FDA Progress On Sonelokimab Draws Fresh Investor Attention
Simply Wall St.  ·  06-06 16:12
MoonLake Immunotherapeutics (MLTX) Valuation After FDA Progress On Sonelokimab Draws Fresh Investor Attention
MoonLake Immunotherapeutics signs commercial supply pact with Vetter Pharma for prefilled application systems
Reuters  ·  06-01
MoonLake Immunotherapeutics signs commercial supply pact with Vetter Pharma for prefilled application systems
Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR), MoonLake Immunotherapeutics (MLTX) and Dogwood Therapeutics (DWTX)
TIPRANKS  ·  05-20
Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR), MoonLake Immunotherapeutics (MLTX) and Dogwood Therapeutics (DWTX)
LifeSci Capital Sticks to Their Buy Rating for MoonLake Immunotherapeutics (MLTX)
TIPRANKS  ·  05-16
LifeSci Capital Sticks to Their Buy Rating for MoonLake Immunotherapeutics (MLTX)
MoonLake Immunotherap Is Maintained at Buy by Needham
Dow Jones  ·  05-12
MoonLake Immunotherap Is Maintained at Buy by Needham
Needham Sticks to Its Buy Rating for MoonLake Immunotherapeutics (MLTX)
TIPRANKS  ·  05-12
Needham Sticks to Its Buy Rating for MoonLake Immunotherapeutics (MLTX)
MoonLake Immunotherapeutics : Needham Raises Target Price to $30 From $25
THOMSON REUTERS  ·  05-12
MoonLake Immunotherapeutics : Needham Raises Target Price to $30 From $25
MoonLake Immunotherapeutics: Buy Rating Reiterated on De-Risked Path to 2026 BLA and Robust SLK Data; $30 Price Target Maintained
TIPRANKS  ·  05-12
MoonLake Immunotherapeutics: Buy Rating Reiterated on De-Risked Path to 2026 BLA and Robust SLK Data; $30 Price Target Maintained
Phil Nadeau Reiterates Buy on MoonLake Immunotherapeutics as Sonelokimab Advances Toward 2027 Launch with $3B+ Peak Sales Potential
TIPRANKS  ·  05-11
Phil Nadeau Reiterates Buy on MoonLake Immunotherapeutics as Sonelokimab Advances Toward 2027 Launch with $3B+ Peak Sales Potential
MoonLake Q1 net loss widens 71.9% to $69.7 million
Reuters  ·  05-11
MoonLake Q1 net loss widens 71.9% to $69.7 million
MoonLake Immunotherapeutics reports results for the quarter ended March 31 - Earnings Summary
Reuters  ·  05-11
MoonLake Immunotherapeutics reports results for the quarter ended March 31 - Earnings Summary
Analysts Are Bullish on These Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Axsome Therapeutics (AXSM)
TIPRANKS  ·  05-11
Analysts Are Bullish on These Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Axsome Therapeutics (AXSM)
MoonLake Immunotherap Is Maintained at Buy by HC Wainwright & Co.
Dow Jones  ·  05-11
MoonLake Immunotherap Is Maintained at Buy by HC Wainwright & Co.
MoonLake Immunotherapeutics Q1 Net Loss Widens
MT Newswires Live  ·  05-11
MoonLake Immunotherapeutics Q1 Net Loss Widens
MoonLake FDA meeting yields ‘best-in-class’ label, says Clear Street
TIPRANKS  ·  05-11
MoonLake FDA meeting yields ‘best-in-class’ label, says Clear Street
MoonLake says aligned with FDA on submission plans for sonelokimab
TIPRANKS  ·  05-11
MoonLake says aligned with FDA on submission plans for sonelokimab

Introduction

Company Name.
MoonLake Immunotherapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or axial spondyloarthritis. MoonLake Immunotherapeutics was incorporated in 2021 and is headquartered in Zug, Switzerland.
Issue price:
--